OCT 03, 2018 12:00 PM PDT

Using CRISPR and Stem Cells to Treat Genetic Disease

Presented At CRISPR 2018
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Investigator, Gladstone Institute of Cardiovascular Disease, Professor Department of Medicine, Division of Genomic Medicine, University of California, San Francisco
    Biography
      Bruce R. Conklin is an Investigator at the Gladstone Institutes and a Professor at UCSF in the departments of Medicine, Ophthalmology and Pharmacology. Conklin is also the Deputy Director of the Innovative Genomics Institute. His research focuses on biomedical applications of CRISPR technology with an emphasis on allele-specific editing of dominant negative disease genes in the retina, motor neurons and cardiac tissue. Conklin uses patient-specific iPSC-derived tissues for pre-clinical genome surgery studies. Conklin began research training with Julius Axelrod, Ph.D., (Nobel Laureate, NIH), did his residency at Johns Hopkins and a postdoctoral fellowship with Henry Bourne (UCSF). In 1995 Conklin joined the Gladstone Institutes and UCSF as faculty. Conklin is the founder of several public stem cell and genomics projects including BayGenomics, GenMAPP and WikiPathways. He pioneered the use of designer G protein coupled receptors (RASSLs) for tissue engineering. He is the Gladstone Scientific Officer for Technology & Innovation. He serves on multiple scientific advisory boards including the Allen Institute for Cell Science, Chinese University of Hong Kong, Tenaya Therapeutics and the Exploratorium. He is a member of the American Society for Clinical Investigation, and is a Fellow in the California Academy of Sciences.

    Abstract:

    Decoding human genetic disease allows us to develop models of the pathology that can be directly tested with gene correction or targeted drug therapy.  Dominant negative mutations are particularly promising therapeutic targets since they are resistant to traditional therapies, yet precise excision of disease-causing allele could provide a cure. We are using patient-derived induced pluripotent stem cells (iPSCs) to model diseases in tissues that are particularly susceptible to dominant negative mutations: cardiomyocytes, motor neurons and retinal pigment epithelial (RPE) cells. By developing CRISPR genome surgery in human cells, we hope to devise improved cellular models as well as human therapies.  By focusing on allele-specific gene excision we can select gene mutations that are highly penetrant, with clear phenotypes in cell types that can be readily derived from iPSCs.  We use whole genome sequencing to identify common genetic polymorphisms that can be used to selectively inactivate the disease allele with CRISPR nucleases.  The diseased cell types allow us to decode the cellular signatures of disease and determine if the excision of the disease allele restores cellular functioning.  Genome surgery is a rapidly advancing field that uses state-of-the-art techniques that pushes the boundaries of cell and molecular biology. We use advanced microscopy, tissue engineering and single cell genomics to optimize precise editing. We are developing computational methods to select optimal CRISPR/Cas9 combinations in diverse populations. We aim to produce therapies that are safe and cost effective so that they can benefit the maximal number of people. In collaboration with clinical scientists and the Innovative Genomics Institute (https://innovativegenomics.org/) we are preparing large animal models and clinical grade reagents to prepare for human clinical trials.  

    Learning Objectives: 

    1. Specific examples of where genome surgery could be used
    2. Future directions in genome surgery


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    Loading Comments...